Editorial: The World Health Organization (WHO) Updated List of Emerging and Potentially Pandemic Pathogens Includes Yersinia pestis as Plague Vaccines Await Clinical Trials.
{"title":"Editorial: The World Health Organization (WHO) Updated List of Emerging and Potentially Pandemic Pathogens Includes Yersinia pestis as Plague Vaccines Await Clinical Trials.","authors":"Dinah V Parums","doi":"10.12659/MSM.948672","DOIUrl":null,"url":null,"abstract":"<p><p>The importance of rapidly developing and distributing safe and effective vaccines was a major lesson from the COVID-19 pandemic, which drove new vaccine development technologies. In May 2024, the World Health Organization (WHO) updated the identification of bacterial pathogens of importance to public health as guidance for research and development of strategies to prevent and overcome global antimicrobial resistance (AMR). In June 2024, the WHO updated the 2017-18 list of priority pathogens to provide a scientific framework for epidemic and pandemic preparedness. The 2024 updated WHO list of priority pathogens also recognizes emerging infections and historical former pandemic infections, including Yersinia pestis, the cause of bubonic, pneumonic, and septicemic plague. Between 2010 and 2019, the six countries with the most reported human cases of Yersinia pestis infection (from highest to lowest) were Madagascar, the Congo, Uganda, Peru, Tanzania, and the USA, with a total of 4,547 cases with a mortality rate of 17% (786 cases). More than 20 candidate plague vaccines are in the preclinical phase, with few in early (phase 1) clinical trials. This editorial highlights the need for continued review of potential pandemic pathogens and the re-emergence of plague, which awaits a vaccine.</p>","PeriodicalId":48888,"journal":{"name":"Medical Science Monitor","volume":"31 ","pages":"e948672"},"PeriodicalIF":3.1000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Science Monitor","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12659/MSM.948672","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
The importance of rapidly developing and distributing safe and effective vaccines was a major lesson from the COVID-19 pandemic, which drove new vaccine development technologies. In May 2024, the World Health Organization (WHO) updated the identification of bacterial pathogens of importance to public health as guidance for research and development of strategies to prevent and overcome global antimicrobial resistance (AMR). In June 2024, the WHO updated the 2017-18 list of priority pathogens to provide a scientific framework for epidemic and pandemic preparedness. The 2024 updated WHO list of priority pathogens also recognizes emerging infections and historical former pandemic infections, including Yersinia pestis, the cause of bubonic, pneumonic, and septicemic plague. Between 2010 and 2019, the six countries with the most reported human cases of Yersinia pestis infection (from highest to lowest) were Madagascar, the Congo, Uganda, Peru, Tanzania, and the USA, with a total of 4,547 cases with a mortality rate of 17% (786 cases). More than 20 candidate plague vaccines are in the preclinical phase, with few in early (phase 1) clinical trials. This editorial highlights the need for continued review of potential pandemic pathogens and the re-emergence of plague, which awaits a vaccine.
期刊介绍:
Medical Science Monitor (MSM) established in 1995 is an international, peer-reviewed scientific journal which publishes original articles in Clinical Medicine and related disciplines such as Epidemiology and Population Studies, Product Investigations, Development of Laboratory Techniques :: Diagnostics and Medical Technology which enable presentation of research or review works in overlapping areas of medicine and technology such us (but not limited to): medical diagnostics, medical imaging systems, computer simulation of health and disease processes, new medical devices, etc. Reviews and Special Reports - papers may be accepted on the basis that they provide a systematic, critical and up-to-date overview of literature pertaining to research or clinical topics. Meta-analyses are considered as reviews. A special attention will be paid to a teaching value of a review paper.
Medical Science Monitor is internationally indexed in Thomson-Reuters Web of Science, Journals Citation Report (JCR), Science Citation Index Expanded (SCI), Index Medicus MEDLINE, PubMed, PMC, EMBASE/Excerpta Medica, Chemical Abstracts CAS and Index Copernicus.